Ruiz-Irastorza G, Barreiro G, Aguirre C
Service of Internal Medicine, Hospital de Cruces, Bizkaia, Basque Country, Spain.
Br J Haematol. 1996 Dec;95(4):611-2. doi: 10.1046/j.1365-2141.1996.d01-1952.x.
Bone marrow toxicity, mainly neutropenia, has been described as an uncommon secondary effect of most beta-lactams, and it is usually related to large cumulative doses. Although previously described for piperacillin, no cases of marrow depression caused by piperacillin/tazobactam have been reported to date. We report a case of reversible pancytopenia, with evidence of bone marrow depression, which occurred after a 17 d course of piperacillin/tazobactam. The drug was given to an underweight 18-year-old woman, at the usual dosage of 4/0.5 g three times a day. We stress the need for reducing the recommended dosage when treating underweight adult patients, and also of monitoring haematological parameters during prolonged treatments.
骨髓毒性，主要是中性粒细胞减少，已被描述为大多数β-内酰胺类药物罕见的副作用，通常与大的累积剂量有关。虽然之前已有哌拉西林骨髓毒性的报道，但迄今为止，尚无哌拉西林/他唑巴坦引起骨髓抑制的病例报告。我们报告1例可逆性全血细胞减少症，有骨髓抑制证据，该病例发生在哌拉西林/他唑巴坦治疗17天后。患者为1名体重不足的18岁女性，按每日3次、每次4/0.5 g的常规剂量给药。我们强调，在治疗体重不足的成年患者时需要降低推荐剂量，并且在长期治疗期间要监测血液学参数。
